Key result
Novel cancer therapeutics, including tyrosine kinase inhibitors and immunotherapies, are associated with diverse cardiovascular toxicities such as vascular disease, hypertension, and arrhythmias.
The field of cardio-oncology must expand beyond anthracycline-induced heart failure to recognize and manage the diverse cardiovascular toxicities associated with novel targeted and immunologic cancer therapies.
No takes yet. Share an insight, caveat, or question.
Clinicians should monitor for vascular, hypertensive, and arrhythmic toxicities with novel cancer therapies; extends cardio-oncology scope but leaves optimal management strategies open.
Michael G. Fradley (2016) conducted a review in Cancer and cardiovascular toxicity. Novel cancer therapeutics (TKIs, PIs, IMiDs, immunotherapies) was evaluated. Novel cancer therapeutics, including tyrosine kinase inhibitors and immunotherapies, are associated with diverse cardiovascular toxicities such as vascular disease, hypertension, and arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: